Rydapt and Hospitalisation - a phase IV clinical study of FDA data

Summary:

Hospitalisation is reported as a side effect among people who take Rydapt (midostaurin), especially for people who are female, 50-59 old, have been taking the drug for 1 - 6 months also take Lisinopril, and have Acute myeloid leukaemia.

The phase IV clinical study analyzes which people have Hospitalisation when taking Rydapt. It is created by eHealthMe based on reports of 2,005 people who have side effects when taking Rydapt from the FDA, and is updated regularly.

What is Rydapt?

Rydapt has active ingredients of midostaurin. eHealthMe is studying from 2,005 Rydapt users. Check the latest studies of Rydapt.

What is Hospitalisation?

Hospitalisation is found to be associated with 1,716 drugs and 1,135 conditions by eHealthMe. Check the latest studies of Hospitalisation.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 27, 2026

2,005 people reported to have side effects when taking Rydapt.
Among them, 43 people (2.14%) have Hospitalisation.

Among these 43 people:

How long have people been on Rydapt when they have Hospitalisation? *

What is the gender of people who have Hospitalisation when taking Rydapt? *

female: 52.38 %
male: 47.62 %

What is the age of people who have Hospitalisation when taking Rydapt? *

What are other drugs people take besides Rydapt? *

What are other side effects people have besides Hospitalisation? *

Memory Loss: 1 person, 2.33%
Leukaemia (blood or bone marrow cancer): 1 person, 2.33%

What are the existing conditions these people have? *

Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 24 people, 55.81%
Acute Monocytic Leukaemia (a type of blood cancer): 3 people, 6.98%
Leukaemia (blood or bone marrow cancer): 2 people, 4.65%
Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 2 people, 4.65%
Systemic Mastocytosis (a condition caused by the accumulation of mast cells in more than one part of the body): 1 person, 2.33%
Malignant Mast Cell Neoplasm (cancerous tumour of mast cell (immune cell)): 1 person, 2.33%
Idiopathic Urticaria (allergic reactions, presence of hives with unknown cause): 1 person, 2.33%
Cytomegalovirus Infection: 1 person, 2.33%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 1 person, 2.33%
Acute Myeloid Leukaemia (In Remission): 1 person, 2.33%

* Approximation only. Some reports may have incomplete information.

Do you take Rydapt and have Hospitalisation?

- Check whether Hospitalisation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rydapt:

Rydapt (2,005 reports)

Hospitalisation treatments and more:

Hospitalisation (143,651 reports)

Browse all side effects of Rydapt:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hospitalisation:

Hospitalisation (1,716 drugs)

Browse all the conditions that are associated with Hospitalisation:

Hospitalisation (1,135 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on midostaurin (the active ingredients of Rydapt) and Rydapt (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.